Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy

This study is a multicenter, single-arm, phase II clinical trial, aiming to evaluate the safety and efficacy of tumor bed dose escalation radiotherapy for patients with primary breast lesions achieving pCR (ypT0) after neoadjuvant chemotherapy and breast-conserving surgery.

Trial Details

NCT ID

NCT07113613

Phase

PHASE2

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Exemption from additional radiotherapy on the tumor bed after surgery

Locations (sample)

Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

(1) Voluntary participation, good compliance, able to cooperate with the trial observation, and having signed a written informed consent form; (2) …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →